HC
Therapeutic Areas
Stoke Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zorevunersen (STK-001) | Dravet Syndrome | Phase 3 |
| STK-002 | Autosomal Dominant Optic Atrophy (ADOA) | Preclinical |
| Undisclosed TANGO ASO | SYNGAP1-Related Intellectual Disability | Discovery |
Leadership Team at Stoke Therapeutics
EM
Edward M. Kaye, M.D.
Chief Executive Officer
AR
Adrian R. Krainer, Ph.D.
Founder
IA
Isabel Aznarez, Ph.D.
Founder & Former Head of Discovery
BT
Barry Ticho, M.D., Ph.D.
Chief Medical Officer
SJ
Stephen J. Tulipano, CPA
Chief Financial Officer
AA
Arthur A. Levin, Ph.D.
Executive VP, Platform Biology